用于治疗阿尔茨海默病的抗淀粉样蛋白疗法：终于，给患者带来了好消息。 - Suppr

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients.

作者信息

Ramanan Vijay K, Day Gregory S

机构信息

Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA.

Department of Neurology, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA.

出版信息

Mol Neurodegener. 2023 Jun 28;18(1):42. doi: 10.1186/s13024-023-00637-0.

DOI:10.1186/s13024-023-00637-0

PMID:37381015

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10304213/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/386f/10304213/c16be5af2ccc/13024_2023_637_Fig1_HTML.jpg

相似文献

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients.

Mol Neurodegener. 2023 Jun 28;18(1):42. doi: 10.1186/s13024-023-00637-0.

Alzheimer's disease: where next for anti-amyloid therapies?

Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023.

Mol Neurodegener. 2023 Sep 25;18(1):66. doi: 10.1186/s13024-023-00656-x.

Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials.

J Alzheimers Dis. 2022;90(4):1395-1399. doi: 10.3233/JAD-220841.

Identification of amyloid antibodies for Alzheimer disease - immunotherapy.

Arch Physiol Biochem. 2022 Oct;128(5):1275-1282. doi: 10.1080/13813455.2020.1767147. Epub 2020 May 25.

A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned.

Neurodegener Dis Manag. 2019 Jun;9(3):119-121. doi: 10.2217/nmt-2019-0006. Epub 2019 May 22.

Reconsidering and Reforming the Amyloid Cascade Hypothesis.

Curr Protein Pept Sci. 2021;22(6):449-457. doi: 10.2174/1389203722666210322151627.

Generic inhibition of amyloidogenic proteins by two naphthoquinone-tryptophan hybrid molecules.

Proteins. 2012 Aug;80(8):1962-73. doi: 10.1002/prot.24080. Epub 2012 May 26.

PET Amyloid Analyses.

J Nucl Med. 2016 Aug;57(8):1168-9. doi: 10.2967/jnumed.116.173989. Epub 2016 Apr 14.

Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials.

J Nucl Med. 2022 Jun;63(6):830-832. doi: 10.2967/jnumed.121.263694.

引用本文的文献

Preliminary Investigation of the Association Between Epigenetic Aging Acceleration and Amyloid Biomarkers in Bipolar Disorder.

Am J Geriatr Psychiatry. 2025 Jul 5. doi: 10.1016/j.jagp.2025.06.008.

Photobiomodulation mitigates blood-brain barrier disruption in APP/PS1 mouse model of Alzheimer's disease by activating the AMPK pathway.

Alzheimers Res Ther. 2025 Jun 23;17(1):141. doi: 10.1186/s13195-025-01787-7.

Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.

Nat Commun. 2025 Jun 17;16(1):5292. doi: 10.1038/s41467-025-60628-1.

Avenanthramide-C as Alzheimer's Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models.

Cells. 2025 Jun 2;14(11):826. doi: 10.3390/cells14110826.

Exploring biomarkers of neurodegeneration in epilepsy: Critical insights.

Epileptic Disord. 2025 Jun;27(3):341-357. doi: 10.1002/epd2.70023. Epub 2025 Apr 8.

Aloe-Emodin Improves Mitophagy in Alzheimer's Disease via Activating the AMPK/PGC-1α/SIRT3 Signaling Pathway.

CNS Neurosci Ther. 2025 Mar;31(3):e70346. doi: 10.1111/cns.70346.

Dysregulated Neurotransmission and the Role of Viruses in Alzheimer's Disease.

ACS Chem Neurosci. 2025 Mar 19;16(6):982-987. doi: 10.1021/acschemneuro.4c00763. Epub 2025 Mar 5.

Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease.

Alzheimers Dement. 2025 Mar;21(3):e14602. doi: 10.1002/alz.14602.

Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer's Disease.

Mol Neurobiol. 2025 Feb 21. doi: 10.1007/s12035-024-04484-y.

Cathepsin B prevents cell death by fragmentation and destruction of pathological amyloid fibrils.

Cell Death Discov. 2025 Feb 15;11(1):61. doi: 10.1038/s41420-025-02343-w.

本文引用的文献

Lecanemab: Appropriate Use Recommendations.

J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.

Expectations and clinical meaningfulness of randomized controlled trials.

Alzheimers Dement. 2023 Jun;19(6):2730-2736. doi: 10.1002/alz.12959. Epub 2023 Feb 7.

Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.

N Engl J Med. 2023 Feb 2;388(5):478-479. doi: 10.1056/NEJMc2215148. Epub 2023 Jan 4.

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.

Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2.

Lecanemab in Early Alzheimer's Disease.

N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Neurology. 2022 Apr 12;98(15):619-631. doi: 10.1212/WNL.0000000000200176. Epub 2022 Feb 23.

Inclusion of Underrepresented Groups in Preclinical Alzheimer Disease Trials-Opportunities Abound.

JAMA Netw Open. 2021 Jul 1;4(7):e2114606. doi: 10.1001/jamanetworkopen.2021.14606.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Nat Rev Neurol. 2019 Feb;15(2):73-88. doi: 10.1038/s41582-018-0116-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献